Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

2.

Teaching removable partial denture design: 'METACIEL', a novel digital procedure.

Bonnet G, Lance C, Bessadet M, Tamini F, Veyrune JL, Francois O, Nicolas E.

Int J Med Educ. 2018 Jan 26;9:24-25. doi: 10.5116/ijme.5a5b.2b0d. No abstract available.

3.

A new digital denture procedure: a first practitioners appraisal.

Bonnet G, Batisse C, Bessadet M, Nicolas E, Veyrune JL.

BMC Oral Health. 2017 Dec 20;17(1):155. doi: 10.1186/s12903-017-0440-z.

4.

Predictive Parameters of Oral Health Quality of Life in Complete Mandibular Denture Wearers Stabilized by Mini-Implants: A Two-Year Follow-Up Study.

Batisse C, Bonnet G, Veyrune JL, Nicolas E, Bessadet M.

Materials (Basel). 2017 Oct 19;10(10). pii: E1197. doi: 10.3390/ma10101197.

5.

Influence of the renewal of removable dentures on oral health related quality of life.

Bonnet G, Batisse C, Segyo JW, Veyrune JL, Nicolas E, Bessadet M.

Springerplus. 2016 Nov 28;5(1):2019. eCollection 2016.

6.

Stabilization of mandibular complete dentures by four mini implants: Impact on masticatory function.

Batisse C, Bonnet G, Bessadet M, Veyrune JL, Hennequin M, Peyron MA, Nicolas E.

J Dent. 2016 Jul;50:43-50. doi: 10.1016/j.jdent.2016.04.012. Epub 2016 May 2.

PMID:
27151558
7.

Ceramo-Metal Crown or Cad-Cam Rehabilitation: Patient and Practitioner Appraisal.

Batisse C, Bessadet M, Decerle N, Veyrune JL, Nicolas E.

Eur J Prosthodont Restor Dent. 2014 Dec;22(4):159-65.

PMID:
26466440
8.

Evaluation of Cerec endocrowns: a preliminary cohort study.

Decerle N, Bessadet M, Munoz-Sanchez ML, Eschevins C, Veyrune J, Nicolas E.

Eur J Prosthodont Restor Dent. 2014 Jun;22(2):89-95.

PMID:
25134368
9.

DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.

Moreaux J, Bruyer A, Veyrune JL, Goldschmidt H, Hose D, Klein B.

Br J Haematol. 2014 Feb;164(4):613-6. doi: 10.1111/bjh.12660. Epub 2013 Nov 13. No abstract available.

10.

Impact of removable partial denture prosthesis on chewing efficiency.

Bessadet M, Nicolas E, Sochat M, Hennequin M, Veyrune JL.

J Appl Oral Sci. 2013 Sep-Oct;21(5):392-6. doi: 10.1590/1679-775720130046.

11.

Geriatric slim implants for complete denture wearers: clinical aspects and perspectives.

Huard C, Bessadet M, Nicolas E, Veyrune JL.

Clin Cosmet Investig Dent. 2013 Aug 28;5:63-8. doi: 10.2147/CCIDE.S47743. eCollection 2013.

12.

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.

Moreaux J, Reme T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.

Br J Cancer. 2013 Aug 6;109(3):676-85. doi: 10.1038/bjc.2013.392. Epub 2013 Jul 18.

13.

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Kassambara A, Schoenhals M, Moreaux J, Veyrune JL, Rème T, Goldschmidt H, Hose D, Klein B.

PLoS One. 2013 Apr 30;8(4):e62752. doi: 10.1371/journal.pone.0062752. Print 2013.

14.

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Schoenhals M, Kassambara A, Veyrune JL, Moreaux J, Goldschmidt H, Hose D, Klein B.

Haematologica. 2013 Sep;98(9):1442-9. doi: 10.3324/haematol.2012.066944. Epub 2013 Apr 12.

15.

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G, Veyrune JL, Olivier G, Cartron G, Rossi JF, Klein B.

Oncotarget. 2012 Nov;3(11):1335-47.

16.

Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.

Moreaux J, Rème T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.

Mol Cancer Ther. 2012 Dec;11(12):2685-92. doi: 10.1158/1535-7163.MCT-12-0721. Epub 2012 Oct 18.

17.

Changes in mastication after an immediate loading implantation with complete fixed rehabilitation.

Veyrune JL, Opé S, Nicolas E, Woda A, Hennequin M.

Clin Oral Investig. 2013 May;17(4):1127-34. doi: 10.1007/s00784-012-0787-0. Epub 2012 Jul 20.

PMID:
22814760
18.

Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins.

Schoenhals M, Frecha C, Bruyer A, Caraux A, Veyrune JL, Jourdan M, Moreaux J, Cosset FL, Verhoeyen E, Klein B.

Leukemia. 2012 Jul;26(7):1663-70. doi: 10.1038/leu.2012.36. Epub 2012 Feb 9.

PMID:
22318450
19.

Nutritional status, dietary intake and oral quality of life in elderly complete denture wearers.

Cousson PY, Bessadet M, Nicolas E, Veyrune JL, Lesourd B, Lassauzay C.

Gerodontology. 2012 Jun;29(2):e685-92. doi: 10.1111/j.1741-2358.2011.00545.x. Epub 2011 Oct 17.

PMID:
22004061
20.

Effect of dental status on changes in mastication in patients with obesity following bariatric surgery.

Godlewski AE, Veyrune JL, Nicolas E, Ciangura CA, Chaussain CC, Czernichow S, Basdevant A, Hennequin M.

PLoS One. 2011;6(7):e22324. doi: 10.1371/journal.pone.0022324. Epub 2011 Jul 20.

21.

A six-month assessment of oral health-related quality of life of complete denture wearers using denture adhesive: a pilot study.

Nicolas E, Veyrune JL, Lassauzay C.

J Prosthodont. 2010 Aug;19(6):443-8. doi: 10.1111/j.1532-849X.2010.00601.x. Epub 2010 Apr 29.

PMID:
20456031
22.

The masticatory normative indicator.

Woda A, Nicolas E, Mishellany-Dutour A, Hennequin M, Mazille MN, Veyrune JL, Peyron MA.

J Dent Res. 2010 Mar;89(3):281-5. doi: 10.1177/0022034509357022. Epub 2010 Jan 29.

PMID:
20118433
23.

Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.

Condomines M, Veyrune JL, Larroque M, Quittet P, Latry P, Lugagne C, Hertogh C, Kanouni T, Rossi JF, Klein B.

J Immunol. 2010 Jan 15;184(2):1079-84. doi: 10.4049/jimmunol.0804159. Epub 2009 Dec 4.

24.

APRIL is overexpressed in cancer: link with tumor progression.

Moreaux J, Veyrune JL, De Vos J, Klein B.

BMC Cancer. 2009 Mar 16;9:83. doi: 10.1186/1471-2407-9-83.

25.

[Obesity and oral health: risk factors of obese patients in dental practice].

Godlewski AE, Veyrune JL, Nicolas E.

Odontostomatol Trop. 2008 Sep;31(123):25-32. French.

PMID:
19266847
26.

Masticatory dysfunction in persons with Down's syndrome. Part 2: management.

Faulks D, Mazille MN, Collado V, Veyrune JL, Hennequin M.

J Oral Rehabil. 2008 Nov;35(11):863-9. doi: 10.1111/j.1365-2842.2008.01878.x. Epub 2008 Sep 12.

PMID:
18793251
27.

Masticatory dysfunction in persons with Down's syndrome. Part 1: aetiology and incidence.

Faulks D, Collado V, Mazille MN, Veyrune JL, Hennequin M.

J Oral Rehabil. 2008 Nov;35(11):854-62. doi: 10.1111/j.1365-2842.2008.01877.x. Epub 2008 Aug 12.

PMID:
18702629
28.

Impact of morbid obesity on chewing ability.

Veyrune JL, Miller CC, Czernichow S, Ciangura CA, Nicolas E, Hennequin M.

Obes Surg. 2008 Nov;18(11):1467-72. doi: 10.1007/s11695-008-9443-9. Epub 2008 Mar 26.

PMID:
18368460
29.

CD200: a putative therapeutic target in cancer.

Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B.

Biochem Biophys Res Commun. 2008 Feb 1;366(1):117-22. Epub 2007 Dec 4.

PMID:
18060862
30.

Validation of video versus electromyography for chewing evaluation of the elderly wearing a complete denture.

Nicolas E, Veyrune JL, Lassauzay C, Peyron MA, Hennequin M.

J Oral Rehabil. 2007 Aug;34(8):566-71.

PMID:
17650166
31.

Mastication of model products in complete denture wearers.

Veyrune JL, Lassauzay C, Nicolas E, Peyron MA, Woda A.

Arch Oral Biol. 2007 Dec;52(12):1180-5. Epub 2007 Jun 18.

PMID:
17572377
32.

Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.

Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, Redal N, Duperray C, De Vos J, Klein B.

Eur Cytokine Netw. 2005 Jan-Mar;16(1):57-64.

33.

Clinical evaluation of mastication: validation of video versus electromyography.

Hennequin M, Allison PJ, Veyrune JL, Faye M, Peyron M.

Clin Nutr. 2005 Apr;24(2):314-20.

PMID:
15784494
34.

Impact of new prostheses on the oral health related quality of life of edentulous patients.

Veyrune JL, Tubert-Jeannin S, Dutheil C, Riordan PJ.

Gerodontology. 2005 Mar;22(1):3-9.

PMID:
15747892
35.

The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N, Shaughnessy J Jr, Klein B.

Br J Haematol. 2004 May;125(3):373-82.

36.

A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.

Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G, Klein B.

Oncogene. 2003 May 15;22(19):2950-9.

37.
38.

Consequences of oral rehabilitation on dyskinesia in adults with Down's syndrome: a clinical report.

Faulks D, Veyrune JL, Hennequin M.

J Oral Rehabil. 2002 Mar;29(3):209-18.

PMID:
11896836
39.

[Removable prosthesis: masticatory efficiency].

N'Dindin AC, Compagnon D, Veyrune JL, Morenas M, Bitty MJ.

Odontostomatol Trop. 1999 Mar;22(85):15-22. French.

PMID:
11372098
40.

mRNA localization by a 145-nucleotide region of the c-fos 3'--untranslated region. Links to translation but not stability.

Dalgleish G, Veyrune JL, Blanchard JM, Hesketh J.

J Biol Chem. 2001 Apr 27;276(17):13593-9. Epub 2001 Jan 3.

41.

Prevalence of oral health problems in a group of individuals with Down syndrome in France.

Hennequin M, Allison PJ, Veyrune JL.

Dev Med Child Neurol. 2000 Oct;42(10):691-8.

42.
43.

Localisation of a reporter transcript by the c-myc 3'-UTR is linked to translation.

Dalgleish GD, Veyrune JL, Accornero N, Blanchard JM, Hesketh JE.

Nucleic Acids Res. 1999 Nov 15;27(22):4363-8.

44.

A novel calcium signaling pathway targets the c-fos intragenic transcriptional pausing site.

Coulon V, Veyrune JL, Tourkine N, Vié A, Hipskind RA, Blanchard JM.

J Biol Chem. 1999 Oct 22;274(43):30439-46.

45.

Significance of oral health in persons with Down syndrome: a literature review.

Hennequin M, Faulks D, Veyrune JL, Bourdiol P.

Dev Med Child Neurol. 1999 Apr;41(4):275-83. Review. No abstract available.

46.

Development of a synthetic bolus using silicone elastomer for the study of masticatory efficiency.

Compagnon D, Veyrune JL, Morenas M, Faulks D.

J Prosthet Dent. 1999 Jun;81(6):704-9.

PMID:
10347359
47.

The proto-oncogene c-fos increases the sensitivity of keratinocytes to apoptosis.

Mils V, Piette J, Barette C, Veyrune J, Tesnière A, Escot C, Guilhou JJ, Basset-Séguin N.

Oncogene. 1997 Apr 3;14(13):1555-61.

48.

3' untranslated regions of c-myc and c-fos mRNAs: multifunctional elements regulating mRNA translation, degradation and subcellular localization.

Veyrune JL, Hesketh J, Blanchard JM.

Prog Mol Subcell Biol. 1997;18:35-63. Review. No abstract available.

PMID:
8994260
50.

c-fos mRNA instability determinants present within both the coding and the 3' non coding region link the degradation of this mRNA to its translation.

Veyrune JL, Carillo S, Vié A, Blanchard JM.

Oncogene. 1995 Nov 16;11(10):2127-34. Erratum in: Oncogene 1996 Jun 6;12(11):2479.

PMID:
7478533

Supplemental Content

Loading ...
Support Center